Jean Pierre
Non-Executive Chairman
Healthcare
Compass Oncology
Bahamas
Biography
In addition to his role as Chairman of the Board of Alzheon, Dr. Garnier serves as Chairman of the Board of Directors for the Swiss biopharmaceutical company Idorsia, a spinout from Actelion. Dr. Garnier chaired Actelion leading its acquisition by Johnson & Johnson in 2017 for $30 billion. Dr. Garnier is a director of United Technologies Corporation and an Operating Partner at Advent International, a private equity firm. He is a member of the board of trustees of Newman’s Own Foundation and a trustee of The Max Planck Institute.
Research Interest
In addition to his role as Chairman of the Board of Alzheon, Dr. Garnier serves as Chairman of the Board of Directors for the Swiss biopharmaceutical company Idorsia, a spinout from Actelion. Dr. Garnier chaired Actelion leading its acquisition by Johnson & Johnson in 2017 for $30 billion. Dr. Garnier is a director of United Technologies Corporation and an Operating Partner at Advent International, a private equity firm. He is a member of the board of trustees of Newman’s Own Foundation and a trustee of The Max Planck Institute.
